August / September #9 : Nonoxynol? Nein! - by Scott Williams

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Archives » POZ Magazine issues

Table of Contents

The Lady Is a Champ

Women on the Verge

Expecting the Worst

Time Trials

Heaven Can Wait

Writing Wrongs

Nonoxynol? Nein!

The Perez Family

No Relief for Gay Men of Color


Putting the Dis in Disability

ER Hath A Way With AIDS

Start Making Sense

Mama's Boy

An Effort for A

Hades Home Journal

Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

email print

August / September 1995

Nonoxynol? Nein!

by Scott Williams

Vaginal microbicides may do more harm than good

Is a squirt of foam or dollop of gel likely to meet a woman's HIV prevention needs? Far from it, according to most research that's been conducted on vaginal microbicides -- those HIV-killing chemicals found in some foams, gels and lubes.

Historically, women have borne most of the responsibility in preventing unwanted pregnancy. With HIV prevention, however, the reverse is true. Besides Reality, the relatively expensive and thus far less-than-popular female condom, the woman-only arsenal of HIV prophylactics consists solely of vaginal microbicides. These agents -- which kill bacteria, viruses and parasites -- have limited effectiveness in preventing HIV transmission and may actually increase a woman's risk of infection.

Nonoxynol-9 and octoxynol-9 -- both commonly found in gels, foams, suppositories and lubricants -- are the only two vaginal microbicidal agents currently approved in the United States.

"Such compounds have the potential to cause significant vaginal irritation that may actually augment the risk of HIV transmission," write Christopher Elias and Lori Heise of the New York City-based Population Council.

Vaginal microbicides are only one piece of the HIV prevention puzzle. Researchers say development of additional female-controlled HIV prevention options are slow in coming because of gender bias, the unprofitability of microbicides and manufacturers' fear of product-liability suits.

The Philadelphia-based pharmaceutical company Biosyn currently is testing the vaginal microbicide C31G in a phase I safety trial. Test results of C31G thus far show the drug to have a lower tissue irritation level than nonoxynol-9 and to have activity against a broad spectrum of sexually transmitted diseases. Other vaginal microbicides in the drug pipeline are in even more preliminary testing stages than C31G. None of these products are likely to make it to the neighborhood drug store for several years.

HIV infection rates are skyrocketing among women worldwide, and the lack of inexpensive, safe, female-controlled prevention methods is partly responsible for this global explosion. Sadly, many women remain uninformed as broad medical research on vaginal microbicides continues to be neglected.

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Did you participate in an event for National Black HIV/AIDS Awareness Day 2016?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.